Health Products

Taisho Pharmaceutical Pabron Gold A (Granules) unlicensed product:, product is labelled to contain dihydrocodeine phosphate that is listed on Schedule I of the CDSA

· Published by Health Canada · Official notice

Details

Alert type: Health product recall
Category: Health products - Drugs
Product: Taisho Pharmaceutical Pabron Gold A (Granules)
Issue: Health products - Product safety
What to do: Consult your health care professional if you have any health concerns.
Audience: General public, Healthcare, Industry
Recall class: Type II
Get told about the next health product recall.

We email or text you when Canada issues a recall that matches what you watch: a brand, a product, an allergen. Most never make the news.

Get health product recall alerts

CA$3.99/mo · cancel anytime

Products

LotProduct NameMarket AuthorizationBrand Product NameDosage FormStrength
AllTaisho Pharmaceutical Pabron Gold ANo market authorizationTaisho Pharmaceutical Pabron Gold AGranulesGuaifenesin 60 mg, Dihydrocodeine phosophate 8 mg, dl-Methylephedrine Hydrochloride 20 mg, Acetaminophen 300 mg, Chlorpheniramine Maleate 2.5 mg, Anhydrous Caffeine 25 mg, Riboflavin 4 mg

Issue

Product sold without market authorization (DIN) in Canada. Product is labelled to contain dihydrocodeine phosphate that is listed on Schedule I of the Controlled Drugs and Substances Act. Product is labelled to contain guaifenesin, dl-methylephedrine hydrochloride, acetaminophen, chlorpheniramine maleate and caffeine that may pose a risk to health.

Get told about the next health product recall.
Get health product recall alerts

CA$3.99/mo · cancel anytime